Cycle 1 grants · $50,000 in awards of $5,000 to $30,000 · file by 22 DecemberCycle 1 grants · $50,000 · file by 22 Dec

Legal

Grant Selection Policy

NEXUM ANALYTICS LTD · Version 1.3 · Effective 20 October 2026

1. Purpose, scope and funding

1.1 Why the house gives grants. An examination ends with a keystone: the assumption the model rests on, and the test that would settle it. Most founders know that test and cannot afford to run it. The house funds the test. A grant is paid against the milestone that produces the number, and the number goes into the record.

The house backs its own judgment with its own capital. An award is the house saying, in the one form that cannot be faked, that it would stand behind this record.

The house is made of the records that held. A business that excels with a signed examination behind it is what the house exists to find, and its record is permanent. Awards and their outcomes are published by examination reference, held or not.

1.2 Purpose. This policy sets out how NEXUM ANALYTICS LTD (company number 17440513, registered office 66 Paul Street, London, EC2A 4NA, United Kingdom; "Nexum" or "the house") selects recipients of its grants and governs each grant from award to completion.

1.3 Scope. It applies to every grant cycle, every member of the grants committee, the independent reviewer, every examining analyst or reviewer who takes part in a grant decision, and every recipient.

1.4 Funding. Grants are funded solely from Nexum's own funds. No third party contributes to a grant allocation, and no grant is made on behalf of anyone else.

1.5 Nature of a grant. A grant is a discretionary payment for a stated purpose. It is not repayable, except where an award rests on a material misrepresentation, or grant funds are misapplied or left unspent when the Grant Agreement ends, as the Grant Agreement provides. It gives Nexum no shares, equity, debt, revenue share, return or other interest in the recipient, and it is not an investment, a loan or a security.

1.6 Separation. Members of the Founding Faculty have no role in any grant decision, ranking or payment. Grants are kept separate from the house's introduction service.

1.7 Related documents. This policy works with Nexum's internal AML, Fraud and Sanctions Policy, the Grants section of the nexum.fund Terms, and the Grant Agreement signed with each recipient. Where they differ for a particular grant, the signed Grant Agreement prevails.

1.8 Taxes. Each recipient is responsible for any tax due on a grant in its own jurisdiction. The house may ask for the tax forms it needs to make a payment.

2. Cycles and eligibility

2.1 Cycles. Grants are considered in cycles. Cycle 1, the founding cycle, opened on 7 October 2026 and closes on 5 January 2027. Each later cycle runs for 90 days and opens the day after the previous cycle closes.

2.2 What is published at opening. For each cycle, Nexum publishes at opening the allocation, the amount range for a single grant, any amount carried from the previous cycle, and the last filing date. Grants are awarded within that range until the allocation is used or no further record meets the standard. A cycle runs on the terms published when it opened, subject to 4.9.

2.3 Which cycle considers a record. A record that has been opted in under 2.5 is considered in the cycle in which it is filed, provided it is filed no later than fourteen days before that cycle closes (the last filing date); a record filed later is considered in the next cycle. A record filed by the last filing date and delivered after the cycle closes is considered in that cycle on delivery. Cycle 1 considers every record filed by 22 December 2026, whether its examination fee was paid at the founding price, at the standard price, or waived. The founding price is a term of the examination service and has no bearing on grant eligibility.

2.4 Tracks. Records are considered in two tracks by the service examined: Standard for companies not yet earning, Advanced for companies already earning. A record upgraded to an Advanced examination is considered in the Advanced track.

2.5 Opting in. A founder opts in on the Nexum platform at any time from filing the examination until the cycle that considers the record closes; a founder who opts in after that is considered in the next cycle. Opting in confirms that the company is, or will be before it signs the Grant Agreement, a registered legal entity with a business account in its own name; that it is not connected with a comprehensively sanctioned jurisdiction or owned or controlled by a designated person; that no member of the grants committee or close relation of one holds an interest in it; that the founder accepts this policy; and that an award, if made, is announced under 4.7. Opting in carries no fee, and the examination service paid for has no bearing on any grant decision. When opting in, the founder states the amount sought within the published range and, in no more than 150 words, which test from the examination the money runs and what number it produces; the statement can be revised until the cycle closes.

2.6 Not considered. The following are not considered: a record whose examination fee was refunded; an examination the house declined; a record withdrawn by its founder; a test record; a company in which a member of the grants committee, or a close relation of one, holds an interest; a company without a built product, meaning a product a user outside the team can use today, live, in beta or in a paid pilot; and a business outside the fields the house examines, namely AI-native products, developer infrastructure, software and automation, fintech, marketplaces, and games, gambling products excluded.

2.7 Who can be paid. A grant can be paid only to a registered legal entity that holds a business account in its own name and passes the checks in the AML, Fraud and Sanctions Policy. Companies connected with a comprehensively sanctioned jurisdiction, or owned or controlled by a designated person, cannot receive a grant.

2.8 Repeat awards and re-entry. A company may receive one grant in any twelve months. A record Declined in a cycle is considered again in a later cycle once a new house event, a re-examination or a verified milestone, has been entered on it and its founder opts in again.

3. Selection

3.1 The grants committee. Grant decisions are made by a committee of at least two members appointed by Nexum's board of directors, together with an independent reviewer from outside the house who has no tie to any founder or company considered in the cycle and has signed the house's confidentiality undertaking. The independent reviewer reads every shortlisted record and co-signs every decision. Their names, and any substitute appointed under 4.6, are kept in the committee register.

3.2 Process. Within 7 days of a cycle's close, or of the delivery of the last record filed by its last filing date if that is later, the committee shortlists from the considered records. The committee then speaks with each shortlisted founder individually, by call or in writing, and records each conversation with the decision. Within 7 days of that conversation, the founder submits a grant plan of no more than one page, confirming or revising the amount sought within the published range, setting out the use of funds, and proposing two or three milestones with the evidence that will prove each. The committee announces its decisions within four weeks of the cycle's close.

3.3 Criteria. Selection is competitive and rests on the delivered examination. The committee weighs first the business itself, meaning a real product, a problem the team owns and a case the house would stand behind, and then: the strength and verifiability of the evidence in the record; the decision the examination served, and what the founder has done since; what the grant settles, meaning the test the examination named, and whether the grant produces its answer within the tranche period; whether the grant plan's milestones are concrete, proportionate and verifiable; and the integrity of the record, including the founder's candour on weaknesses the examination found. Annex A sets out what a score of 0, 1, 3 and 5 means on each criterion.

3.4 Scoring. Each committee member scores every considered record from 0 to 5 on each criterion in 3.3, against Annex A, and records the scores before seeing any other member's. The criteria are weighted: the business 25%, evidence 20%, the decision and what followed 15%, what the grant settles 15%, milestones 15%, and integrity 10%. A member's shortlist score is the weighted average of every criterion except milestones, with those weights rescaled to total 100%, scored from the record and the founder's opt-in statement. A record is shortlisted only if every member's shortlist score reaches 3.0 and no member scores any criterion 0. The milestones criterion is scored on the grant plan. A record's final score is the average of the members' weighted scores on all six criteria. Each track is ranked on its own by final score. The committee divides the allocation between the tracks according to the strength of the records in each, and awards follow each track's ranking. The committee may award less than the amount sought, within the published range. A tie goes to the higher evidence score.

3.5 Outcomes. Each shortlisted record is Awarded, Deferred to the next cycle (reconsidered there without a new examination), or Declined. A considered record that is not shortlisted is Declined for that cycle.

3.6 The allocation. The committee intends to award each cycle's published allocation to records that meet its standard. Any amount not awarded carries into the next cycle and is published at nexum.fund/grants. No company is entitled to a grant, and the committee does not award a grant to make up the allocation.

3.7 Decisions and reasons. An award requires the agreement of every committee member and of the independent reviewer, each recorded from their own account. Every decision, positive or negative, carries a written rationale kept with the record. Every shortlisted founder receives a short written summary of the committee's reasons; any other founder considered may ask for one. Decisions are final and are not subject to appeal.

4. Award, tranches, conflicts and review

4.1 Agreement and verification. An award takes effect only when the recipient signs Nexum's Grant Agreement and passes the checks in the AML, Fraud and Sanctions Policy. An award lapses if either is not completed within 45 days of the decision, unless the committee extends the period in writing. The house may ask for further documents at any stage, before the award, before any tranche or during the term, according to the company, its jurisdiction, its ownership and the size of the grant; no payment is made until they are provided.

4.2 Tranches. Each grant is paid in two or three tranches over a term of up to 9 months. The first tranche is paid on signature and verification. Each later tranche is released against milestone evidence accepted by an examining analyst of the house; the final tranche is released only on verified completion. The first tranche is no more than 40% of the grant and the final tranche no less than 20%. Before any payment, the Grant Agreement sets the amount of each tranche, its milestone and the evidence that proves it. The house assesses milestone evidence within 10 business days and pays an accepted tranche within 10 business days of acceptance; a tranche whose milestone is not met by the end of the term lapses.

4.3 Evidence. Milestone evidence is filed on the Nexum platform and timestamped there, so that every release rests on a dated record.

4.4 Use of funds. Recipients apply grant funds only to the purpose stated in the Grant Agreement. Nexum may ask how a released tranche was applied before releasing the next.

4.5 Withholding and cancellation. Nexum withholds further tranches where evidence is insufficient, where the stated purpose is no longer served, or where misuse is suspected. Where funds are misapplied, or an award rests on a material misrepresentation, Nexum may cancel the grant and require repayment of the amounts concerned. Funds left unspent when the Grant Agreement ends are returned to Nexum.

4.6 Conflicts of interest. A committee member, the independent reviewer or an analyst with a personal, financial or professional tie to a founder or company declares it and recuses from that record; the recusal is logged. Having examined or reviewed a record is not such a tie. Where a committee member recuses, the record is decided by the remaining members and the independent reviewer. Where the independent reviewer recuses, the board appoints a substitute from outside the house on the same terms; if none can be appointed before the shortlist is set, the record is Deferred to the next cycle. Grants to related parties, and any circular or collusive arrangement, are prohibited.

4.7 Publication. Nexum announces each award on its register when it is made, in the mode the founder chose for the entry: the track, the amount and the cycle, with the company's name for a named entry, or its examination reference for a blind entry. Opting in includes acceptance of that announcement. Nexum may also publish aggregate figures for each cycle. When an award's final tranche is paid or withheld, the house publishes its milestone outcomes by examination reference.

4.8 Review. The board reviews this policy after each cycle closes and on any material change to Nexum's model or to applicable law. Each review is recorded with its date and outcome.

4.9 Transition. Version 1.3 applies to Cycle 1 from its effective date. No record was opted in under Version 1.2, so no election or revision is offered. A founder who opted in under Version 1.1 may elect, by notice to the house before Cycle 1 closes, to be considered under Version 1.1.

Annex A — Scoring anchors

Criterion5310
The business (25%)A product in regular use by people outside the team; the team holds an unusual claim on the problem (has lived it, sells into it, or has access others lack); a case the house would sign under its own nameBuilt and used, the problem real; the team's claim on it, or the case, is only partly shownBuilt but barely used; a problem any team could holdNo built product, or no problem the record shows
Evidence (20%)The figures the case rests on are measured, and the house checked them against a source (exports, invoices, analytics)The key figures are measured; the rest are estimates with a stated basisMostly estimates and targetsThe record's central figures are contradicted by its own evidence
The decision, and what followed (15%)The founder took the decision the examination served, or deferred it for a stated reason, and dated action since can be checkedThe decision is taken; action is under way and not yet visibleNo decision yet, and no reason givenThe record names no decision
What the grant settles (15%)The grant runs the test the examination named and produces its answer within the tranche period, at a cost the amount sought matchesThe grant runs the named test, but produces its answer only in part, or after the tranche periodThe grant funds work around the named test without producing its answerNo test from the examination is named
Milestones (15%, scored on the grant plan)Two or three outcomes, each measurable, dated within nine months, and provable by evidence the house can check without relying on the founder's wordMeasurable and dated; the evidence is founder-reportedActivities in place of outcomesNo milestones
Integrity (10%)The founder named the weaknesses the examination found before being asked, answered every question fully, and corrected their own errorsAccepted the hard findings when shown, and answered fullyPartial or evasive answersA material misrepresentation in the record, which also excludes it
GrantsTerms of ServicePrivacy PolicyCookie NoticeConfidentialityRefund PolicyContent Policy